Ulipristal Acetate on Progesterone Levels and Glycodelin-A Endometrial Pattern
Status:
Unknown status
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Controlled ovarian stimulation (COS) for FIV increases progesterone (P) and estradiol (E2)
serum levels in supraphysiologic concentrations at the end of follicular phase. Elevated
serum P levels leads to an accelerated endometrial maturation which interferes with the
dialogue between embryo and endometrium. It has been reported that serum progesterone levels
≥ 1.5 ng/ml on the last day of COS are related to a significant decrease in the ongoing
pregnancy rate following IVF cycles. Also, it has been reported a significant alteration in
the endometrial gene expression profile related to P elevated levels.
Glycodelin-A is an immunomodulatory glycoprotein synthesized by luteal-phase endometrial
epithelium and its expression seems to be related to the action of P. Because glycodelin-A
has immunosuppressive activity, it may facilitate the process of implantation and the
maintenance of pregnancy.
It is already know that ulipristal acetate (UPA) decrease serum P levels. The hypothesis of
this study is that UPA is been able to modify P serum levels and glycodelin-A endometrial
expression pattern on FSH/GnRH Antagonist cycles for FIV.